The medication is commonly used to support dogs with congestive heart failure (CHF), particularly when the condition is associated with faulty heart valves. It is relevant for managing conditions such as CHF stemming from degenerative mitral valve disease and may assist with the related signs of systemic fluid overload, including instances where the failure is specifically caused by valvular dysfunction.

“The medication provides support that helps ease the overall symptom burden.”

---

Managing Progressive Congestive Heart Failure

This medication is commonly used for the long-term management of chronic conditions like CHF. It may assist with maintaining functional stability and is applied when symptomatic support is needed for chronic conditions.

Alleviating Respiratory Distress and Systemic Fluid Overload

It is applied in addressing the distressing symptoms caused by systemic fluid overload, such as persistent coughing and difficulty breathing (dyspnoea). This supportive relief supports the patient during difficult episodes by easing distress and may help manage the overall symptom load.

---

Quick Fact: Relief for Respiratory Distress

Supportive Role in Chronic Cardiac Regimens

Prilactone chiens is integrated as an adjunctive therapeutic agent to complement other primary cardiac treatments. This approach is considered relevant for managing fluid control when additional symptomatic support is needed and plays a role in supporting general well-being during symptomatic phases.

The official regulatory profile for Prilactone chiens defines strict population rules based on physiological status, age, and existing medical conditions. The medicine is authorized only for use in adult dogs for the treatment of congestive heart failure.

Contraindicated Populations (Absolute Exclusion)

• Reproductive Status: Do not use in animals intended for breeding or in bitches that are pregnant or lactating.
• Metabolic Conditions: Prohibited in dogs suffering from hypoadrenocorticism, hyperkalaemia (high potassium), or hyponatraemia (low sodium).
• Drug Combination: Contraindicated in dogs with renal insufficiency if they are simultaneously administered Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
• Hypersensitivity: Do not use in cases of known hypersensitivity to the active substance, spironolactone, or any excipients.

Restricted and Conditional Use

• Age: The product is not recommended for administration to growing dogs due to potential antiandrogenic effects.
• Renal Impairment: Use requires regular monitoring of both renal function and plasma potassium levels, as there may be an increased risk of hyperkalaemia.
• Hepatic Dysfunction: Care should be taken when treating dogs with liver impairment, as the medicine undergoes extensive hepatic biotransformation.

Interactions with other medicines and products

Official regulatory information describes several specific interaction patterns for Spironolactone, the active ingredient in Prilactone chiens, focusing on pharmacokinetic modulation and pharmacodynamic effects.

Pharmacodynamic and Pharmacokinetic Interactions

Interacting Substance/Class	Documented Interaction Pattern
ACE Inhibitors & Potassium-Sparing Drugs	Co-administration may potentially lead to hyperkalaemia (elevated plasma potassium) due to additive potassium-retaining effects.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	May cause a moderate reduction of the natriuretic effects (salt and water excretion) of Spironolactone. Combination is contraindicated in dogs with renal insufficiency.
Digoxin	Spironolactone is documented to decrease Digoxin elimination, leading to raised plasma concentrations of Digoxin.
Other Medicinal Products	Spironolactone may affect the metabolism of other drugs by causing both induction and inhibition of Cytochrome P450 (CYP) enzymes.

Administration Constraints and Specific Populations

Administration with food is officially noted to ensure better bioavailability of the product. Additionally, dogs with pre-existing renal impairment face an increased risk of hyperkalaemia when Spironolactone is co-administered with ACE Inhibitors, underscoring a population-specific caution documented in regulatory labeling.

The action of Prilactone chiens (Spironolactone) is purely mechanistic, targeting the final pathways of hormonal signaling and tissue structure. The drug's mechanism involves competitive blockade at the Mineralocorticoid Receptor (MR).

Blocking Mineralocorticoid Receptor Signaling

This drug is a competitive antagonist that binds to the Mineralocorticoid Receptor (MR) in the body, which normally responds to the hormone aldosterone. The binding by Spironolactone and its active metabolites prevents aldosterone from triggering changes in gene transcription that regulate sodium/potassium exchange. This inhibition begins the mechanistic cascade by modulating signaling within the body's fluid and structural regulatory pathways.

---

Dual Effect on Fluid Balance and Tissue Structure

The mechanism produces a dual physiological effect. In the kidneys, MR blockade prevents the synthesis of proteins required for sodium ( Na^+) reabsorption and potassium ( K^+) excretion, resulting in potassium ion ( K^+) conservation and fluid volume modulation. Simultaneously, the blockade of MR in the heart and blood vessels inhibits chronic cellular pathways that promote inflammation and the deposition of fibrous collagen (fibrosis), inhibiting tissue remodeling pathways.

How to Use Prilactone chiens

Prilactone chiens is administered strictly by the oral route using the palatable, scored tablets. Official instructions govern the precise dosing and timing of administration to ensure proper use, particularly concerning chronic conditions requiring long-term treatment.

---

Official Administration Guidelines

Property	Instruction
Route of Administration	Oral use (Per os) via chewable tablets.
Dosing Schedule	Fixed dose of 2 mg of Spironolactone per kg of the dog's body weight.
Frequency	Administered once daily (q24h).
Timing in Relation to Meals	Must be administered with food (a meal) to significantly increase bioavailability and absorption.

---

Procedural and Population Constraints

The required dose must be achieved by accurately determining the dog's body weight, utilizing the tablet's score lines for precise division into halves or quarters. Any resulting unused divided portions must be returned to the blister and used within seven days. The treatment course is typically considered unlimited for the long-term management of chronic cardiac conditions.

Specific constraints on use exist for certain populations. The product is not recommended for administration to growing dogs. Furthermore, care should be taken when using the product in dogs with hepatic dysfunction due to the drug's extensive biotransformation in the liver. These procedural steps and population constraints define the standardized approach to its correct administration.

Research evidence / Overview of studies for Prilactone chiens

---

Evidence for use in Type 2 Diabetes Mellitus

Prilactone chiens (spironolactone) was studied for research exploring outcomes related to systemic or functional imbalance, which are commonly measured in this condition. Research has included large, randomized controlled trials (RCTs) over short time periods. The focus was observed in studies that monitored changes in the blood marker Hemoglobin A1c (HbA1c) and other measurements. The findings describe patterns observed in the studies where participants reported measurements of HbA1c levels, with differences observed when compared to control groups. Comparative evidence is lacking to fully contextualize the observed patterns against other research.

---

Evidence for use in Chronic Kidney Disease

Research exploring this compound in the context of Chronic Kidney Disease (CKD) was evaluated in large-scale studies, including placebo-controlled RCTs that included patients with pre-existing CKD. Research examined the potential influence on outcomes related to physiological strain, focusing on kidney-specific markers like estimated Glomerular Filtration Rate (eGFR) and Urinary Albumin-to-Creatinine Ratio (UACR). Studies reported eGFR measurements, with observed patterns of change in the studied groups when compared to control groups. Evidence is limited regarding the full range of effects in patients with the most severe stages of CKD.

---

Evidence for use in Chronic Heart Failure

Research has explored this compound in patient populations with Chronic Heart Failure (CHF), conditions marked by functional limitations, through phase 3 RCTs. These studies were studied for their potential to influence outcomes monitoring physiological stress, such as cardiovascular death or hospitalization. Research described how patient-reported experiences evolved in the observed populations where the compound was studied alongside existing background therapy. Subgroup findings are uncertain regarding patterns in patients with multiple complex medical conditions.

---

What is still uncertain about Prilactone chiens

This section clarifies the primary evidence gaps and questions that remain for future research. There is limited information for long-term outcomes across all indications, and follow-up durations were limited in many studies. The available evidence generally describes group patterns but cannot forecast individual outcomes in special populations. The research provides context but not individual predictions. The evidence highlights what is known — and what is still uncertain — about the compound’s patterns.

Common questions about Prilactone chiens (FAQ)

---

Q: What is the difference between Prilactone and other heart medications for dogs?

Prilactone chiens belongs to the pharmacological class known as Mineralocorticoid Receptor Antagonists (MRA). Its active substance, spironolactone, works by acting as a specific antagonist of aldosterone, a hormone that is associated with long-term changes to the heart and blood vessels. This unique mechanism is intended to modulate fluid balance and help inhibit chronic tissue changes, differentiating its mechanism from other general cardiovascular agents.

Q: Is it common for dogs to experience increased urination while taking Prilactone?

The mechanism of Prilactone involves fluid volume modulation by increasing the excretion of sodium and water from the body. This action may lead to observable effects such as increased thirst and urination in the treated dog. While the official safety profile lists specific common side effects, the effect on fluid balance is consistent with the drug's intended action.

Q: Can I crush the Prilactone tablet to give it to my dog?

Official administration instructions specify how to divide the tablet accurately into halves or quarters to achieve the correct dose. These instructions recommend administering the divided portions or whole tablets with food. Regulatory documents do not provide instructions regarding crushing the tablet into a powder, only dividing the scored tablet.

Q: What do studies say about the long-term use of Prilactone in dogs?

For chronic cardiac conditions, official documentation describes the treatment course as typically unlimited. Research supporting the product has examined its use in long-term therapy, noting patterns associated with preventing progressive left ventricle dysfunction and attenuating certain structural changes in the heart in observed experimental dog models.

Q: Does Prilactone help reduce fluid buildup in the lungs?

The drug's action in the kidney results in a decrease in extracellular fluid volume throughout the body. This in turn reduces cardiac preload and left atrial pressure. This overall mechanism of fluid volume support is relevant to the fluid imbalance pathways associated with congestive heart failure.

Q: Can Prilactone change a dog's blood pressure?

Prilactone modulates the body's fluid volume by promoting the excretion of sodium and water. By acting on fluid balance, the drug can affect the pressures within the circulatory system, such as cardiac preload. Regulatory summaries do not typically detail systemic blood pressure changes as a primary outcome.

Q: What information is available about research on Prilactone side effects?

The safety profile, informed by clinical studies, classifies possible adverse reactions by frequency. The official documents list prostatic atrophy in entire male dogs as a Very Common effect (affecting more than 1 in 10 animals) and vomiting and diarrhoea as Common effects (affecting 1 to 10 in 100 animals). This information provides the officially classified frequency of adverse reactions.

Q: What happens if my dog accidentally chews the tablet?

The tablets are designed to be palatable and flavoured, which is why regulatory documents caution that the product should be stored securely out of the reach of animals to prevent accidental ingestion. No specific adverse reaction consequences are listed in the regulatory profile for a dog chewing the tablet outside of the prescribed administration.

Q: What is the typical timeframe before noticing an effect from Prilactone?

The active metabolite of the drug, known as canrenone, generally reaches a stable concentration (steady-state) in the plasma by the third day of once-daily administration. The timeframe for observing the full clinical effect in the treated dog is not explicitly specified in the regulatory summary.

Q: Are there certain breeds of dogs that should not take Prilactone?

Official regulatory documents list contraindications based on pre-existing medical conditions (such as hyperkalaemia or hypoadrenocorticism) and age (it is not recommended for growing dogs). However, the documents do not list specific dog breeds that should not take the medicine.

Q: Is there a specific time of day Prilactone should be given?

The medicine is prescribed to be administered once daily at a fixed dose. Official instructions specify that it must be administered with a meal to enhance absorption, but no specific time of day (such as morning or evening) is mandated for its administration.

Q: How quickly does the active ingredient in Prilactone leave a dog's system?

The parent compound is metabolized rapidly after administration. Its active metabolites, such as canrenone, are eliminated from the plasma with a mean residence time of approximately 11 hours in dogs, according to pharmacokinetic studies.

Q: Do studies support the use of Prilactone in mild heart disease?

The active ingredient, spironolactone, has been included in clinical trials and combination products approved for the management of clinical signs of mild, moderate, or severe congestive heart failure in dogs. This research context indicates the active ingredient has been examined across a range of disease severities.

Q: Is it normal for a dog to seem tired when starting Prilactone?

The official safety profile for the product does not list lethargy (tiredness) as a Common or Very Common adverse reaction. However, regulatory research in which the active ingredient was used in combination with other heart medications has noted lethargy as an observed effect.

Storage and Disposal Requirements

Storage Condition Type	Requirement
Temperature and Environment	The veterinary medicinal product does not require any special temperature storage conditions for the intact package.
Packaging	Store in the original package; partially used tablets must be returned to the opened blister.
In-Use Stability	The shelf-life after first opening the immediate packaging (for part-used tablets) is typically 72 hours (3 days).

All tablets must be stored out of the sight and reach of children and out of the reach of animals to prevent accidental ingestion. Disposal of any unused veterinary medicinal product or waste materials must be done in accordance with local requirements. The official label states that the medicine should not be disposed of via wastewater.